BIM expression in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib in Colombia.

被引：0
|
作者：
Cardona, Andres F.
Karachallou, Niki
Drozdowskyj, Ana
Gimenez Capitan, Ana
Angel Molina-Vila, Miguel
Arrieta, Oscar
Carranza, Hernan
Vargas, Carlos A.
Otero, Jorge M.
Rosell, Rafael
机构：
[1] Fdn Santa Fe Bogota, Bogota, Colombia
[2] Pangaea Biotech, Lab Translat Oncol, Barcelona, Spain
[3] Pivotal, Madrid, Spain
[4] Inst Nacl Cancerol INCAN, Mexico City, DF, Mexico
[5] Fdn Santa Fe Bogota, Clin & Traslat Oncol Grp, Bogota, Colombia
[6] Hosp Badalona Germans Trias & Pujol, USP Inst Univ Dexeus, Canc Therapeut Innovat Grp, Catalan Inst Oncol,Pangaea Biotech, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19098
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BIM EXPRESSION AND POLYMORPHISMS IN EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) TREATED WITH ERLOTINIB IN COLOMBIA (CLICAP)
    Cardona Cardona, Andres Felipe
    Arrieta, Oscar
    Karachaliou, Niki
    Drozdowskyj, Ana
    Gimenez Capitan, Ana
    Angel Molina, Miguel
    Carranza, Hernan
    Vargas, Carlos
    Otero, Jorge
    Rojas, Leonardo
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S198 - S199
  • [2] Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p)
    Karachaliou, Niki
    Drozdowskyj, Ana
    Gimenez Capitan, Ana
    Cardona Zorrilla, Andres Felipe
    Gervais, Radj
    Massuti, Bartomeu
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Carcereny Costa, Enric
    Garcia Campeio, Rosario
    Viteri Ramirez, Santiago
    Morales-Espinosa, Daniela
    Verlicchi, Alberto
    Crisetti, Elisabetta
    Chaib, Imane
    Luis Ramirez, Jose
    Ma, Patrick C.
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] The BIM Deletion Polymorphism in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Lee, Ji Yun
    Ku, Bo Mi
    Lim, Sung Hee
    Kim, Haesu
    Yoo, Kwai Han
    Jung, Ki Sun
    Song, Haa-Na
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S580 - S580
  • [4] Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib
    Patel, Suchit H.
    Rimner, Andreas
    Foster, Amanda
    Zhang, Zhigang
    Woo, Kaitlin M.
    Yu, Helena A.
    Riely, Gregory J.
    Wu, Abraham J.
    LUNG CANCER, 2017, 108 : 109 - 114
  • [5] BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
    Niki Karachaliou
    Jordi Codony-Servat
    Cristina Teixidó
    Sara Pilotto
    Ana Drozdowskyj
    Carles Codony-Servat
    Ana Giménez-Capitán
    Miguel Angel Molina-Vila
    Jordi Bertrán-Alamillo
    Radj Gervais
    Bartomeu Massuti
    Teresa Morán
    Margarita Majem
    Enriqueta Felip
    Enric Carcereny
    Rosario García-Campelo
    Santiago Viteri
    María González-Cao
    Daniela Morales-Espinosa
    Alberto Verlicchi
    Elisabetta Crisetti
    Imane Chaib
    Mariacarmela Santarpia
    José Luis Ramírez
    Joaquim Bosch-Barrera
    Andrés Felipe Cardona
    Filippo de Marinis
    Guillermo López-Vivanco
    José Miguel Sánchez
    Alain Vergnenegre
    José Javier Sánchez Hernández
    Isabella Sperduti
    Emilio Bria
    Rafael Rosell
    Scientific Reports, 5
  • [6] BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
    Karachaliou, Niki
    Codony-Servat, Jordi
    Teixido, Cristina
    Pilotto, Sara
    Drozdowskyj, Ana
    Codony-Servat, Caries
    Gimenez-Capitan, Ana
    Angel Molina-Vila, Miguel
    Bertran-Alamillo, Jordi
    Gervais, Radj
    Massuti, Bartomeu
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Carcereny, Enric
    Garcia-Campelo, Rosario
    Viteri, Santiago
    Gonzalez-Cao, Maria
    Morales-Espinosa, Daniela
    Verlicchin, Alberto
    Crisetti, Elisabetta
    Chaib, Imane
    Santarpia, Mariacarmela
    Luis Ramirez, Jose
    Bosch-Barrera, Joaquim
    Felipe Cardona, Andres
    de Marinis, Filippo
    Lopez-Vivanco, Guillermo
    Miguel Sanchez, Jose
    Vergnenegre, Alain
    Hernandez, Jose Javier Sanchez
    Sperduti, Isabella
    Bria, Emilio
    Rosell, Rafael
    SCIENTIFIC REPORTS, 2015, 5
  • [7] Vitamin D enhances erlotinib response in EGFR-mutant non-small cell lung cancer
    Shaurova, Tatiana
    Shoemaker, Suzanne F.
    Hershberger, Pamela A.
    CANCER RESEARCH, 2016, 76
  • [8] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
    Xiong, Liwen
    Lou, Yuqing
    Bai, Hao
    Li, Rong
    Xia, Jinjing
    Fang, Wentao
    Zhang, Jie
    Han-Zhang, Han
    Lizaso, Analyn
    Li, Bing
    Gu, Aiqin
    Han, Baohui
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [9] Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer
    Yetisir, Abdullah Evren
    Paydas, Semra
    Buyuksimsek, Mahmut
    Ogul, Ali
    Kolsuz, Irem
    Kidi, Mehmet Mutlu
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (01) : 285 - 288
  • [10] Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test
    Gadgeel, S.
    Soria, J. C.
    Goldman, J. W.
    Wakelee, H.
    Camidge, D. R.
    Yu, H.
    Varga, A.
    Solomon, B.
    Oxnard, G. R.
    Ou, S. H.
    Papadimitrakopoulou, V.
    Liu, S. V.
    Reckamp, K.
    Spira, A.
    Piotrowska, Z.
    Despain, D.
    Karlovich, C.
    Yurasov, S.
    Sequist, L. V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S628 - S628
12345